Abliva (ABLI) Q3 2024 earnings summary

Executive summary

• Positive interim analysis of the FALCON Phase 2 study for KL1333 increased the likelihood of a successful final readout and regulatory approval for primary mitochondrial disease treatment.

• Additional SEK 42 million in proceeds secured via convertible bond conversion following the interim analysis, supporting ongoing development.

• KL1333 and NV354 both hold Orphan Drug Designation in the US and Europe, with KL1333 also receiving Fast Track status in the US.

• Abliva is focused on building a leading mitochondrial medicine company, aiming for both direct commercialization and out-licensing revenue streams.

Financial highlights

• Net revenues were SEK 0 for both Q3 and the first nine months of 2024, unchanged from the prior year.

• Loss before tax for Q3 was SEK 19.5 million, an improvement from SEK 32.9 million in Q3 2023; nine-month loss before tax was SEK 63.5 million, down from SEK 70.3 million year-over-year.

• Loss per share before dilution was SEK 0.01 for Q3 (vs. SEK 0.03) and SEK 0.05 for the nine months (vs. SEK 0.07) compared to the same periods last year.

• Operating loss for the nine months was SEK 63.8 million, improved from SEK 70.4 million year-over-year.

• Cash and cash equivalents at September 30, 2024, were SEK 46.8 million, down from SEK 58.6 million a year earlier.

Outlook and guidance

• The positive FALCON interim analysis has generated significant momentum and strategic interest, with preparations underway for Wave 2 of the study, subject to financing.

• The Board has initiated a process to secure additional funding to enable execution of Wave 2 and the company's strategy; failure to secure funding could delay the program and impact going concern.

• Commercial projections for KL1333 suggest a potential market exceeding USD 1 billion in peak sales.